Results 11 to 20 of about 24,396 (218)
Molecular OncologyCD47 is best known for its role in tumor immune evasion; however, studies in diverse cell models indicate that it also has cell autonomous, tumor‐promoting functions which are cell type‐ and context‐specific.
Asa P.Y. Lau +8 more
doaj +2 more sources
Targeting CD47 for cancer immunotherapy [PDF]
Journal of Hematology & Oncology, 2021 AbstractMuch progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT ...
Zhongxing Jiang +4 more
openaire +3 more sources
CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. [PDF]
PLoS ONE, 2012 How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells.
Vu Quang Van +12 more
doaj +1 more source
CD47 as a Potential Target to Therapy for Infectious Diseases
Antibodies, 2020 The integrin associated protein (CD47) is a widely and moderately expressed glycoprotein in all healthy cells. Cancer cells are known to induce increased CD47 expression.
Lamin B. Cham +4 more
doaj +1 more source
Frontiers in Oncology, 2020 Purposes: To measure expression levels of CD47 during endometrial carcinoma development, and to determine specific modulatory effects.Methods: CD47 expression levels in endometrial carcinoma tissues and adjacent tissues were analyzed using qRT-PCR.
Yun Liu +6 more
doaj +1 more source
Role of CD47 in Hematological Malignancies [PDF]
Journal of Hematology & Oncology, 2020 AbstractCD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent “don’t eat me” signal to prevent phagocytosis.
Entsar Eladl +6 more
openaire +4 more sources
Frontiers in Drug Discovery, 2023 Cell surface molecules PD-L1 and CD47 are potent inhibitors of adaptive and innate anti-cancer immunity. We sought to generate a safe, therapeutic, bispecific antibody specifically targeting, and blocking both PD-L1 and CD47 inhibitory activity.
Irene Tang +16 more
doaj +1 more source
Frontiers in Oncology, 2019 Knockdown or gene disruption of the ubiquitously expressed cell surface receptor CD47 protects non-malignant cells from genotoxic stress caused by ionizing radiation or cytotoxic chemotherapy but sensitizes tumors in an immune competent host to genotoxic
Sukhbir Kaur +13 more
doaj +1 more source
CD47 expression is critical for CAR T-cell survival in vivo
Journal for ImmunoTherapy of Cancer, 2023 Background CD47 is an attractive immunotherapeutic target because it is highly expressed on multiple solid tumors. However, CD47 is also expressed on T cells.
Stephen Gottschalk +8 more
doaj +1 more source
Circulation Research, 2007 See related article, pages 712–720 Thrombospondin-1 (TSP-1) is a homotrimeric glycoprotein with multiple functional domains that serves as a key mediator of a number of diverse cellular and physiologic processes.1 TSP-1 is the major component of the α granule of platelets.
David J, Kaczorowski, Timothy R, Billiar
openaire +2 more sources